Compare Definium Therapeutics Inc. Common Shares (DFTX) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs International Business Machines Corp — how do they compare? Definium Therapeutics Inc. Common Shares trades at $37.54 (market cap $4.59B), while International Business Machines Corp trades at $226.76 (market cap $213.50B). The key difference: International Business Machines Corp is far larger — about 46.5× Definium Therapeutics Inc. Common Shares's market cap, and International Business Machines Corp pays a 2.98% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and International Business Machines Corp for 88 Days on average.
| DFTX | IBM | |
|---|---|---|
Market Cap | $4.59B | $213.50B |
Volume | 2,103,937 | 8,908,687 |
Sector | Health | Technology |
52-Week High | $48.45 | $329.23 |
52-Week Low | $10.68 | $205.77 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $3.55B | $270.64B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IBM stock trades at $227.44, up 3.14% with recent momentum driven by positive sentiment in the consulting sector following Accenture's strong earnings. The company shows solid fundamentals with 2025 revenue of $67.54B and net income of $10.59B, though technical indicators suggest bearish momentum with the stock trading near resistance at $230. Recent developments include the self-hosted deployment option for IBM Bob AI platform, enhancing enterprise AI sovereignty capabilities.
IBM presents a mixed investment case with strong profitability metrics (15.52% net margin, 34.62% ROE) and analyst consensus price target of $255.50 offering 12% upside potential. However, bearish technical signals, recent earnings miss in Q2 2026, and increased investing cash outflows (-$10.3B in 2025) present near-term headwinds. The stock's valuation at 20.13 P/E appears reasonable given the company's hybrid cloud and AI consulting growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
